The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Deion Sanders could be sticking around Boulder for at least a few more years after the University of Colorado head football ...

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

According to shoppers, one of Costco's best items is their Kirkland Signature Extra Virgin Olive Oil, "particularly the ...

Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19. Does this ...

We believe the new German government’s infrastructure plans have the potential to materially benefit the European high yield ...

From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

By hoodwinking seniors into private Medicare Advantage plans, insurers profit by denying care and bankrupting hospitals.

RIT gives Alfred Davis Awards to a teacher and student for their work on campus and volunteerism in the community.

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...